Clinical Trial

Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLC

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated October 31, 2024 (before its estimated April 2025 completion). Its status may not reflect the trial's current state.
Summary
This open-label, multicenter, randomized phase II study will evaluate the usage of osimertinib alone for brain metastases compared to SRS and osimertinib in patients with newly diagnosed, treatment naiive EGFR positive lung cancer.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2018-12-06; most recent amendment 2024-10-29.
Status change: Recruiting → Active, Not Recruiting 2024-10-29
Status change: Not Yet Recruiting → Recruiting 2019-03-19
Trial Details
NCT Number NCT03769103
Lead Sponsor British Columbia Cancer Agency
Collaborators: AstraZeneca, Princess Margaret Hospital, Canada, Sunnybrook Health Sciences Centre
Conditions Lung Cancer Non-small Cell Stage IV, Brain Metastases
Enrollment 40 participants
Start Date 2019-03-19
Primary Completion 2025-04 (estimated)
Study Completion 2025-04 (estimated)
Updated on ClinicalTrials.gov 2024-10-31